This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Top Stock Reports for UnitedHealth, Danaher & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).
Danaher (DHR) Rides on Business Strength Amid Headwinds
by Zacks Equity Research
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
by Zacks Equity Research
Markel (MKL) first-quarter results reflect improved earned premiums and increased net investment income.
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
by Zacks Equity Research
Honeywell's (HON) first-quarter 2024 revenues increase approximately 3%, driven by strong momentum in the Aerospace Technologies segment.
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
by Zacks Equity Research
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 11.63% and 2.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Honeywell (HON) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Honeywell's (HON) first-quarter results are likely to have benefited from strength across most of its businesses. Weakness in the warehouse automation market might have been a spoilsport.
Why Danaher (DHR) Might Surprise This Earnings Season
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Carlisle (CSL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Carlisle (CSL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
by Zacks Equity Research
Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.
Here's Why Danaher (DHR) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.
Investors Heavily Search Danaher Corporation (DHR): Here is What You Need to Know
by Zacks Equity Research
Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GE Aerospace (GE) Debuts as Aviation-Focused Public Company
by Zacks Equity Research
GE Aerospace (GE) commences its business operations as an independent public company, following the spin-off of the GE Vernova business from General Electric.
Danaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day.
3M (MMM) Completes Divestiture of Its Healthcare Business
by Zacks Equity Research
3M's (MMM) divestment of the healthcare business will enable it to focus more on its core businesses.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Danaher (DHR) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Danaher (DHR) reachead $248.77 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.
Wall Street Analysts See Danaher (DHR) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Danaher (DHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?